|
|
 Previous Article | Table of Contents | Next Article 
Low-dose deoxycoformycin in the treatment of hairy cell leukemia
EH Kraut, BA Bouroncle and MR Grever
Ten patients with progressive hairy cell leukemia were treated with
2'deoxycoformycin (dCF) by intravenous bolus (4 mg/m2) given every other
week. All ten patients are evaluable for response and nine of the ten
patients have achieved a complete remission. In addition to clearing of
hairy cells from the bone marrow, eight patients had resolution of their
monocytopenia. Seven of the nine patients remain in unmaintained remission
with a median duration of 6.2 months. Two patients have had relapse in the
bone marrow alone and continue to have normal peripheral blood counts. They
are being followed without treatment. Toxicity was minimal at this low dose
with one patient having a mild reversible reduction in creatinine
clearance. Four other patients had reversible neutropenia. There were no
significant infections associated with treatment. Low-dose deoxycoformycin
administered intravenously every other week represents an extremely
effective treatment for hairy cell leukemia.
Volume 68,
Issue 5,
pp. 1119-1122,
11/01/1986
Copyright © 1986 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. A. Thomas, S. O'Brien, C. Bueso-Ramos, S. Faderl, M. J. Keating, F. J. Giles, J. Cortes, and H. M. Kantarjian
Rituximab in relapsed or refractory hairy cell leukemia
Blood,
December 1, 2003;
102(12):
3906 - 3911.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Homma, Y. Tanaka, T. Matsushita, K. Yokoyama, H. Matsui, and S. Natori
Adenosine Deaminase Activity of Insect-derived Growth Factor Is Essential for Its Growth Factor Activity
J. Biol. Chem.,
November 16, 2001;
276(47):
43761 - 43766.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. W. Flinn, K. J. Kopecky, M. K. Foucar, D. Head, J. M. Bennett, R. Hutchison, W. Corbett, P. Cassileth, T. Habermann, H. Golomb, et al.
Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin
Blood,
November 1, 2000;
96(9):
2981 - 2986.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Niitsu, Y. Yamamoto-Yamaguchi, T. Kasukabe, J. Okabe-Kado, M. Umeda, and Y. Honma
Antileukemic efficacy of 2'-deoxycoformycin in monocytic leukemia cells
Blood,
August 15, 2000;
96(4):
1512 - 1516.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Niitsu, Y. Yamaguchi, M. Umeda, and Y. Honma
Human Monocytoid Leukemia Cells Are Highly Sensitive to Apoptosis Induced by 2'-Deoxycoformycin and 2'-Deoxyadenosine: Association With dATP-Dependent Activation of Caspase-3
Blood,
November 1, 1998;
92(9):
3368 - 3375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Saven and L. Piro
Newer Purine Analogues for the Treatment of Hairy-Cell Leukemia
N. Engl. J. Med.,
March 10, 1994;
330(10):
691 - 697.
[Full Text]
|
|
|
|
|
